Avalo Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Avalo Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $27.81M | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | $1.15M | Apr 2, 2018 |
| FY2017 | Dec 31, 2015 | $0 | Apr 2, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.0K | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $441.0K | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $1.92M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $18.05M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $5.40M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $6.70M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $6.75M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $7.03M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $27.81M | Mar 18, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($78.26M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($35.13M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($31.54M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($41.66M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($84.38M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($63.50M) | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | ($16.07M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | ($40.05M) | Mar 11, 2020 |
| FY2017 | Dec 31, 2017 | ($3.09M) | Apr 2, 2018 |
| FY2017 | Sep 30, 2017 | $18.72M | Apr 2, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($72.93M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($68.51M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($27.35M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($37.44M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($82.13M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($72.84M) | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | ($16.14M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | ($35.38M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $13.89M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | ($16.08M) | Apr 2, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $5.79M | Mar 18, 2019 |
| FY2017 | Dec 31, 2017 | $1.96M | Apr 2, 2018 |
| FY2017 | Sep 30, 2017 | $965.0K | Apr 2, 2018 |
| FY2017 | Jun 30, 2017 | $494.0K | Apr 2, 2018 |
| FY2017 | Mar 31, 2017 | $953.0K | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | $773.0K | Apr 2, 2018 |
| FY2017 | Sep 30, 2016 | $4.58M | Apr 2, 2018 |
| FY2017 | Jun 30, 2016 | $2.50M | Apr 2, 2018 |
| FY2017 | Mar 31, 2016 | $2.29M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $1.75M | Mar 14, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $10.30M | Mar 29, 2024 |
| FY2023 | Dec 31, 2022 | $20.71M | Mar 29, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($51.46M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($49.06M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($30.68M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($26.75M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($70.89M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($40.54M) | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | ($19.13M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | ($3.13M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $12.58M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | ($14.57M) | Apr 2, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $95.0K | Mar 29, 2023 |
| FY2022 | Dec 31, 2021 | $113.0K | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $63.0K | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $262.0K | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $564.4K | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $23.3K | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $34.9K | Apr 2, 2018 |
| FY2017 | Dec 31, 2015 | $20.0K | Apr 2, 2018 |
| FY2016 | Dec 31, 2014 | $19.5K | Mar 14, 2017 |
| FY2015 | Dec 31, 2013 | $29.3K | Mar 23, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $116.46M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $150.73M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $20.99M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $33.37M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $80.21M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $43.76M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $36.11M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $70.25M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $42.81M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $5.77M | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.41M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $17.70M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $13.69M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $44.28M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $57.13M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $19.19M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $15.11M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $49.34M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $14.95M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $5.56M | Apr 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $83.05M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $133.03M | Mar 23, 2026 |
| FY2025 | Dec 31, 2023 | $7.30M | Mar 23, 2026 |
| FY2024 | Dec 31, 2022 | ($10.92M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | $23.08M | Mar 29, 2024 |
| FY2022 | Dec 31, 2020 | $24.56M | Mar 29, 2023 |
| FY2021 | Dec 31, 2019 | $21.00M | Mar 2, 2022 |
| FY2020 | Dec 31, 2018 | $20.91M | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | $27.86M | Mar 11, 2020 |
| FY2018 | Dec 31, 2016 | $207.0K | Mar 18, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.50M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $10.50M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $10.50M | Mar 20, 2025 |
| FY2024 | Dec 31, 2022 | $14.41M | Mar 20, 2025 |
| FY2022 | Dec 31, 2021 | $14.41M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $14.41M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $14.41M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $14.41M | Mar 11, 2020 |
| FY2019 | Dec 31, 2017 | $12.29M | Mar 11, 2020 |
| FY2018 | Dec 31, 2016 | $0 | Mar 18, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($448.52M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($370.26M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($335.13M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($303.82M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($262.17M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($177.79M) | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | ($114.29M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | ($98.22M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($58.17M) | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | ($70.04M) | Apr 2, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.86M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $134.55M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $7.42M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $13.17M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $54.59M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $18.92M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $3.61M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $10.65M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $2.47M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $5.13M | Apr 2, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (5) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | (7) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | (113) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | (1,063) | Mar 29, 2024 |
| FY2018 | Dec 31, 2018 | (1) | Mar 18, 2019 |
| FY2017 | Dec 31, 2017 | 0 | Apr 2, 2018 |
| FY2017 | Sep 30, 2017 | 0 | Apr 2, 2018 |
| FY2017 | Jun 30, 2017 | 0 | Apr 2, 2018 |
| FY2017 | Mar 31, 2017 | 0 | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | (1) | Apr 2, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (5) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | (20) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | (113) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | (1,063) | Mar 29, 2024 |
| FY2018 | Dec 31, 2018 | (1) | Mar 18, 2019 |
| FY2017 | Dec 31, 2017 | 0 | Apr 2, 2018 |
| FY2017 | Sep 30, 2017 | 0 | Apr 2, 2018 |
| FY2017 | Jun 30, 2017 | 0 | Apr 2, 2018 |
| FY2017 | Mar 31, 2017 | 0 | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | (1) | Apr 2, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 18.51M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | 10.47M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | 801,746 | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 39,294 | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 9.40M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | 75.00M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | 44.38M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | 40.80M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | 31.27M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | 9.43M | Apr 2, 2018 |